Endoluten
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Endoluten is an oral peptide bioregulator derived from the pineal gland, part of Vladimir Khavinson’s framework of organ-specific short-chain peptide complexes. It is marketed as the oral capsule equivalent to Epithalon (an injectable pineal peptide), with a focus on supporting melatonin production and circadian rhythm regulation.
The pineal gland (epiphysis) is central to melatonin synthesis and the body’s circadian timing system, which declines with age. Endoluten is studied primarily in the context of anti-aging and circadian health, with most clinical research conducted in Russia and Eastern Europe. Human trials remain limited and often lack independent replication.
How it works
In preclinical and small clinical studies, Endoluten peptides appear to interact with pineal gland cells to normalize melatonin secretion and restore the circadian rhythm of melatonin release — particularly the nighttime surge that typically flattens with age.
Khavinson’s proposed mechanism involves these short peptide sequences binding to DNA regulatory regions in pineal cells, potentially restoring youthful gene-expression patterns. However, the precise molecular pathways in humans have not been definitively established. Most mechanistic data comes from animal and cell-culture models.
Reported benefits
- Restoration of age-related declines in nighttime melatonin production
- Support for circadian rhythm amplitude and timing
- Potential contribution to hormonal regulation during aging
These are studied effects in small human and animal trials, not assured outcomes.
Considerations & side effects
Because rigorous, large-scale human trials are absent, the long-term safety profile of Endoluten is not well characterized in Western medical literature. Reported side effects are generally mild. Product quality varies in the research-peptide market, and the oral bioavailability of peptide complexes remains uncertain compared to injectable forms.
Endoluten is not a substitute for clinical evaluation and is intended for research contexts only. Anyone considering use should consult a qualified healthcare provider.
Frequently asked
What is Endoluten?
An oral peptide bioregulator derived from the pineal gland, developed as part of the Khavinson framework of short-chain peptide complexes designed to support organ-specific regulatory function.
How does Endoluten differ from Epithalon?
Epithalon (Epitalon) is an injectable form, while Endoluten is an oral capsule form. Both are pineal peptide preparations; Endoluten's oral delivery aims to provide convenience, though absorption pathways differ.
Is Endoluten FDA-approved?
No. Endoluten is not approved by the FDA or any major regulator for therapeutic use and is sold for research purposes only.
What does Endoluten target?
Endoluten is designed to support pineal gland function and melatonin production, with the goal of restoring age-related disturbances in circadian rhythm and hormonal regulation.
What does the research show about pineal peptides?
Small clinical studies and animal research suggest pineal peptide preparations may help normalize melatonin rhythm and reduce some age-related hormonal disturbances, but rigorous human clinical trials are limited.
References
- Korkushko OV, et al. Peptides of pineal gland and thymus prolong human life. ↗
- Khavinson VKh, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. ↗
- Korkushko OV, et al. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. ↗
Related compounds
AEDR tetrapeptide cardiovascular bioregulator. Supports cardiac gene regulation and cardiomyocyte metabolism. Studied for heart health and cardiovascular aging.
Synthetic tetrapeptide that stimulates telomerase production. May support cellular longevity and immune function.
Senolytic peptide that selectively eliminates senescent cells accumulating with aging. Uses D-retro-inverso modification to disrupt the FOXO4-p53 interaction with enhanced stability.